US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Rafael Holdings, Inc. Class B Common Stock
(NY:
RFL
)
1.540
+0.040 (+2.67%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rafael Holdings, Inc. Class B Common Stock
< Previous
1
2
Next >
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
September 30, 2026
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
June 11, 2026
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
June 10, 2026
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
April 22, 2026
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 16, 2026
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
December 11, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
October 29, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
October 28, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
September 16, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
August 27, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
June 18, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
June 11, 2025
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the...
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
June 04, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of
May 20, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
May 05, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
April 29, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role
April 24, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
March 26, 2025
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the...
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
March 13, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
December 11, 2024
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
November 06, 2024
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need
From
Rafael Holdings, Inc.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders
October 07, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
September 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders
September 23, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
September 06, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
August 27, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RFL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders
August 22, 2024
From
Halper Sadeh LLC
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
August 22, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
August 22, 2024
From
Rafael Holdings, Inc.; Cyclo Therapeutics
Via
GlobeNewswire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
June 14, 2024
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
From
Rafael Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
